Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Coenzyme Q10 (CoQ10) is an essential molecule in human body. It acts as an antioxidant, a co-factor for energy conversion in mitochondria and has anti-inflammatory effects capable of improving endothelial function. Our goal is to investigate whether CoQ10 is capable to reduce the incidence of acute kidney injury/failure following cardiac surgery. Cardiac surgery is major risk factor for acute kidney injury/failure (AKI/F).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CoQ10 | Experimental | Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure. |
|
| Placebo | Placebo Comparator | Patients will receive per-orally placebo in three divided doses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Coenzyme Q10 | Dietary Supplement | Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in serum creatinine after cardiac surgery indicating kidney injury. | Increase in serum creatinine as defined by KDIGO stages will be used as indicator of kidney injury. | 7 days |
| Difference in urinary low molekular weight alpha 1 microglobulin as an indicator of kidney tubular injury. | Alpha 1 microglobulin is an indicator of kidney tubular damage, measured in urine. | 3 days |
| Daily urine output during the 72 hours postoperatively. | Urine output less than 0.5 ml/kg/h during 6 hours indicates increased risk of developing AKI. | 3 days |
| Measure | Description | Time Frame |
|---|---|---|
| Length of stay in intensive care unit | Length of stay in intensive care unit will be compared between an intervention and placebo arm of trial. | 10 days |
| Advanced glycation endproducts | Elevated advanced glycation endproducts (AGE) in skin, measured using skin autofluorescence, are reliable predictors of cardiovascular disease and diabetes mellitus. Elevated levels before cardiac surgery should also predict increased risk of intraoperative morbidity, mortality and postoperative complications. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hrvoje Vučemilović, MD | Contact | 00385914444032 | hrvoje.vucemilovic@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Hospital Center Split | Recruiting | Split | Split-Dalmatia County | 21000 | Croatia |
Not provided
| ID | Term |
|---|---|
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C024989 | coenzyme Q10 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 7 days |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |